Nerac

Information That Drives Innovation

We’re here to help with your research needs
+1 860 872 7000
Customer Access
You are here: Home / Nerac Insights / Articles / FDA’s Proposed Regulatory Changes to Laboratory-Developed Tests (LDTs)

FDA’s Proposed Regulatory Changes to Laboratory-Developed Tests (LDTs)

Google+0
LinkedIn15

By Roz Sweeney, Ph.D., Nerac Analyst

Originally Published: November 17th, 2014

Introduction

The FDA recently issued updated draft guidance for proposed regulatory changes affecting laboratory developed tests (LDTs). Laboratory developed tests (or LDTs) are traditionally IVDs developed and used by CLIA labs for treating or testing patients within that lab’s associated healthcare facility. They have historically fallen under FDA enforcement discretion, under the rationale that they fall within the practice of medicine, which is not regulated by the FDA. (While the specific tests are exempt, the labs are regulated under the Clinical Laboratory Improvements Amendment of 1988.)

Over the past 30-40 years, LDT’s have evolved considerably as medicine has gotten more complex. The FDA believes that the claims of certain LDTs are not adequately supported with evidence and that certain LDTs may lack appropriate controls yielding erroneous results. The FDA is aware of harm caused by faulty LDTs. For example, the Agency is aware of harm caused by biomarker tests for early detection of ovarian cancer. In this case, patients received inappropriate treatments or even harmful treatments as a result of these tests.

Other reasons for the need for increased oversight include LDT’s being used on larger populations (e.g. outside of the local healthcare facility) and in situations where more stringently regulated devices exist (e.g. same indication and use as PMA approved devices). The proposed regulations are intended to even the playing field in safety, efficacy, and performance of LDT’s with class I, II, III IVDs.

 

 

 

 

Related Posts

  • In Vitro Diagnostics - Upcoming Regulatory Developments in the U.S. and European Union: Are You Ready for the Transition?
    57
    Join Nerac Regulatory analysts Roz Sweeney, Ph.D. and Donna Mitchell-Magaldi for this powerful discussion designed to give you the insights and information you need on the new EU/FDA regulatory proposals/guidances and how they will be implemented by the agencies!! It is imperative that IVD manufacturers prepare for upcoming/new regulatory changes in both the EU and US.…
    Tags: regulatory, nerac, changes, sweeney, roz, analyst, ph.d, clinical, fda, labs
  • Laboratory-Developed Test Regulations
    54
    By Roz Sweeney, Ph.D., Nerac Analyst Originally Published: September 19th, 2014 Will Laboratory-developed tests (LDTs) require FDA marketing approval? Laboratory-developed tests (LDTs) are in vitro diagnostic tests typically used within a single-institution’s CLIA lab. The FDA exempted clinical laboratories from registration and listing of tests almost 40 years ago; however, this exemption may no longer…
    Tags: tests, ldts, fda
  • Bringing Functional Foods to Market: FDA’s Regulatory Mandate Drives the Process
    50
    Originally published February, 2011 Introduction Bringing a new functional food product to market is a potentially complex process with many decision points driven by the US Food and Drug Administration’s (FDA) regulatory mandate. There is no single definition for functional foods, also known as nutraceuticals. They may encompass a range of products and uses, including…
    Tags: regulatory, fda, read, published, originally